CRISPR Therapeutics starts search for a bioinformatics chief

CRISPR Therapeutics has joined the hunt for bioinformatics talent. Fresh from a $64 million VC round, the CRISPR-Cas9 gene-editing startup is advertising for a head of bioinformatics, putting it in competition with multiple other biotechs that are trying to bolster their ranks of computational biologists.

Bill Lundberg

The Switzerland-originated biotech gave notice of its ambitions in April by poaching Alexion ($ALXN) vet Bill Lundberg to lead its nascent R&D shop in Cambridge, MA. Lundberg is now looking for people to fill a handful of positions as he embarks on a hiring spree that will swell the company's R&D headcount toward 50 by the end of 2016. A head of bioinformatics with a relevant Ph.D. and more than 5 years of experience is on CRISPR Therapeutics' current wish list, requirements that put it up against some heavy hitters in the job market.

A slew of companies, from Big Pharmas such as Johnson & Johnson ($JNJ) and Novartis ($NVS) to deep-pocketed startups like Juno Therapeutics ($JUNO), are seeking candidates with similar skill sets. Tech-focused life science players including Illumina ($ILMN) and J. Craig Venter's Human Longevity are also hiring. And Roche's ($RHHBY) Genentech is still advertising for a replacement for the 23andMe-bound Robert Gentleman, although its requirement of 15 years of experience means it is pitching its search higher than the aforementioned companies.

Each business recognizes that the success of its R&D operation is now tied to bioinformatics. At CRISPR Therapeutics, the person who gets the role will need to build public and private third-party pools of next-generation sequencing data into the R&D programs, while also overseeing the gathering, storage and analysis of results from its in-house activities. CRISPR Therapeutics wants the new hire to use a mix of open-source and third-party tools, as well as proprietary algorithms, to manage these tasks.

- here's the advert

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.